Nicotinic acetylcholine receptors in health and disease

Molecular Neurobiology

Volumn 15, Issue 2, 1997, Pages 193-222

  Lindstrom, Jon ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Alzheimer's disease; Epilepsy; Myasthenia gravis; Nicotine; Nicotinic acetylcholine receptors; Parkinson's disease; Schizophrenia

Indexed keywords

ACETYLCHOLINE; ALCOHOL; ANESTHETIC AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR STIMULATING AGENT; MUSCLE PROTEIN; NERVE PROTEIN; NICOTINE; NICOTINIC RECEPTOR;

ALZHEIMER DISEASE; ANIMAL; AUTOIMMUNE DISEASE; CHEMICAL STRUCTURE; CHEMISTRY; CLASSIFICATION; DRUG EFFECT; EPILEPSY; FEMALE; GENETICS; GILLES DE LA TOURETTE SYNDROME; KERATINOCYTE; MALE; METABOLISM; MYASTHENIA GRAVIS; NEUROMUSCULAR SYNAPSE; PARKINSON DISEASE; PHYSIOLOGY; PREGNANCY; PROTEIN CONFORMATION; REVIEW; SCHIZOPHRENIA; SMOKING; TORPEDO;

ACETYLCHOLINE; ALZHEIMER DISEASE; ANESTHETICS; ANIMALS; AUTOIMMUNE DISEASES; CHOLINERGIC AGENTS; CHOLINERGIC ANTAGONISTS; EPILEPSY; ETHANOL; FEMALE; KERATINOCYTES; MALE; MODELS, MOLECULAR; MUSCLE PROTEINS; MYASTHENIA GRAVIS; NERVE TISSUE PROTEINS; NEUROMUSCULAR JUNCTION; NICOTINE; PARKINSON DISEASE; PREGNANCY; PROTEIN CONFORMATION; RECEPTORS, NICOTINIC; SCHIZOPHRENIA; SMOKING; TORPEDO; TOURETTE SYNDROME;

EID: 0031242019     PISSN: 08937648     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02740634     Document Type: Article

References (225)

1. Akaike A., Tamura Y., Yokota T., Shimohama S., and Kimura J. (1994) Nicotine-induced protection of cultured cortical neurons against N-methyl-D-aspartate receptor-mediated glutamate cytotoxicity. Brain Res. 644, 181-187.
2. Albuquerque E., Alkondon M., Pereira E., Castro N., Schrattenholz A., Barbosa C., Bonfante-Cabarcas R., Aracava Y., Eisenberg H., and Maelicke A. (1996) Properties of neuronal nicotinic acetylcholine receptors, pharmacological characterization and modulation of synaptic function. J. Pharmacol. Exp. Ther. 280, 1117-1136.
3. Akabas M. and Karlin A. (1995) Identification of acetylcholine receptor channel-lining residues in the M1 segment of the a subunit. Biochemistry 34, 12,596-12,500.
4. Akabas M., Kaufmann C., Archdeacon P., and Karlin A. (1994) Identification of acetylcholine receptor channel-lining residues in the entire M2 segment of the a subunit. Neuron 13, 919-927.
5. Akabas M., Stauffer D., Xu M., and Karlin A. (1992) Acetylcholine receptor channel structure probed in cysteine-substitution mutants. Science 258, 307-310.
6. Anand R., Conroy W., Schoepfer R., Whiting P., and Lindstrom J. (1991) Chicken neuronal nicotinic acetylcholine receptors expressed in Xenopus oocytes have a pentameric quaternary structure. J. Biol. Chem. 266, 11,191-11,198.
7. Anand R., Peng X., Ballesta J., and Lindstrom J. (1993) Pharmacological characterization of abungarotoxin sensitive AChRs immuno-isolated from chick retina, contrasting properties of α7 and α8 subunit-containing subtypes. Mol. Pharmacol. 44, 1046-1050.
8. Arcavi L., Jacob P., Hellerstein M., and Benowitz N. (1994) Divergent tolerance to metabolic and cardiovascular effects of nicotine in smokers with low and high levels of cigarette consumption. Clin. Pharmacol. Ther. 56, 55-64.
9. Arneric S., Sullivan J., Briggs C., Donnelly-Roberts D., Anderson D., Roszkiewicz J., Hughes M., Cadman E., Adams P., Garvey D., Wasicak J., and Williams M. (1994) (S)-3methyl-5(1-methyl-2pyrrolidinyl) isoxazole (ABT418), a novel cholinergic ligand with cognition-enhancing and anxiolytic activities, 1. in vitro characterization. J. Pharmacol. Exper. Ther. 270, 310-318.
10. Arnold A. and Trojanowski J. (1996) Recent advances in defining the neuropathy of schizophrenia. Acta Neuropathol. 92, 217-231.
11. Barnard E. (1992) Receptor classes and the transmitter-gated ion channels. TIBS 17, 368-374.
12. Benowitz N. (1996) Pharmacology of nicotine, addiction and therapeutics. Annu. Rev. Pharmacol. Toxicol. 36, 597-613.
13. Benowitz N., Prochet H., and Jacob P. (1990) Pharmacokinetics, metabolism, and pharmacodynamics of nicotine, in Nicotine Psychophamacology (Wonnocott S., Russell M., and Stolerman I., eds.), Oxford Science Publication, Oxford England, pp. 112-157.
14. 3H] nicotine binding sites in human brain. J. Neurochem. 50, 1243-1247.
15. Beroukhim R. and Unwin N. (1995) Three dimensional location of the main immunogenic region of the acetylcholine receptor. Neuron 15, 323-331.
16. Bertrand S., Buisson B., Forster I., and Bertrand D. (1995) Determinants regulating neuronal nicotinic receptor function, in Effects of Nicotine on Biological Systems II, Advances in Pharmacological Sciences (Clarke P., Quik M., Adlkofer F., and Thurau K., eds.), Birkhauser, Basel, pp. 53-59.
17. Betz H. (1990) Homology and analogy in transmembrane channel design, lessons from synaptic membrane proteins. Biochemistry 29, 3591-3599.
18. Bickford P. and Wear K. (1995) Restoration of sensory gating of auditory evoked response by nicotine in fimbria-fornix lesioned rats. Brain Res. 705, 235-240.
19. Birtwiselle J. (1996) The role of cigarettes and nicotine in the onset and treatment of ulcerative colitis. Postgrad. Med. J. 72, 714-718.
20. Bjugstad K., Mahnir V., Kein W., Socci D., and Arendash G. (1996) Long term treatment with GTS-21 or nicotine enhances water maze performance in aged rats without affecting the density of nicotinic receptor subtypes in neocortex. Drug Develop. Res. 39, 19-28.
21. Blomquist O., Engel J., Bissbrandt H., and Soderpalm B. (1993) The mesolimbic dopamine-activating properties of ethanol are antagonized by mecamylamine. Eur. J. Pharmacol. 249, 207-213.
22. Blount P. and Merlie J. (1989) Molecular basis of the two nonequivalent ligand binding sites of the muscle nicotinic acetylcholine receptor. Neuron 3, 349-357.
23. Chan J. and Quik M. (1993) A role for the nicotinic abungarotoxin receptor in neurite outgrowth in PC12 cells. Neuroscience 56, 441-451.
24. Changeux J. (1990) Functional architecture and dynamics of the nicotinic acetylcholine receptor, an allosteric ligand-gated ion channel, in Fidia Research Foundation, Neuroscience Award Lectures, vol. 4, 21-168.
25. 125I] abungarotoxin. J. Neurosci. 5, 1307-1315.
26. Codignola A., Tarroni P., Cattaneo M., Vincentini L., Clementi F., and Sher E. (1994) Serotonin release and cell proliferation are under control of abungarotoxin-sensitive nicotinic receptors in small-cell lung carcinoma cell lines. FEBS Lett. 342, 286-290.
27. Coleman R. (1992) Current drug therapy for Parkinson's disease. A review. Drugs Aging 2, 112-124.
28. Collins A., Burch J., DeFiebre C., and Marks M. (1987) Tolerance and cross tolerance between ethanol and nicotine. Pharmacol. Biochem. Behavior 29, 365-373.
29. Collins A. and Marks M. (1996) Are nicotinic receptors activated or inhibited following chronic nicotine treatment? Drug. Develop. Res. 38, 231-242.
30. Conroy W. and Berg D. (1995) Neurons can maintain multiple classes of nicotinic acetylcholine receptors distinguished by different subunit compositions. J. Biol. Chem. 270, 4424-4431.
31. Conroy W., Vernallis A., and Berg D. (1992) The α5 gene product assembles with multiple acetylcholine receptor subunits to form distinctive receptor subtypes in brain. Neuron 9, 1-20.
32. Conti-Tronconi B., Tzartos S., and Lindstrom J. (1981) Monoclonal antibodies as probes of acetylcholine receptor structure. II, Binding to native receptor. Biochemistry 20, 2181-2191.
33. Cooper E., Couturier S., and Ballivet M. (1991) Pentameric structure and subunit stoichiometry of a neuronal nicotinic acetylcholine receptor. Nature 350, 235-238.
34. Couturier S., Bertrand D., Matter J., Hernandez M., Bertrand S., Millar N., Valera S., Barkas T., and Ballivet M. (1990) Aneuronal nicotinic acetylcholine receptor subunit (α7) is developmentally regulated and forms a homomeric channel blocked by abungarotoxin. Neuron 5, 847-856.
35. Croxen R., Newland C., Beeson D., Oosterhuis H, Chauplannaz G., Vincent A., and Newsome-Davis J. (1997) Mutations in different functional domains of the human muscle acetylcholine receptor α subunit in patients with the slow channel congenital myasthenic syndrome. Human Mol. Genetics 6, 767-774.
36. Czajkowski C. and Karlin A. (1995) Structure of the nicotinic receptor acetylcholine binding site. J. Biol. Chem. 270, 3160-3164.
37. Czajkowski C., Kaufmann C., and Karlin A. (1993) Negatively charged amino acid residues in the nicotinic receptor δ subunit that contribute to the binding of acetylcholine. Proc. Natl. Acad. Sci. USA 90, 6294-6289.
38. Dani J. and Heinemann S. (1996) Molecular and cellular aspects of nicotine abuse. Neuron 16, 905-908.
39. Decker M., Brioni J., Sullivan J., Buckley M., Rodek R., Rasziewicz J., Kang C., Kim D., Giardina W., Wasicak J., Garvey D., Williams M., and Arneric S. (1994) (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl) isoxasole (ABT418), a novel cholinergic ligand with cognition-enhancing and anxiolytic activities, II. in vitro characterization. J. Pharmacol. Exper. Ther. 270, 319-328.
40. Deitrich R., Dunwiddie T., Harris R., and Erwin V. (1989) Mechanism of action of ethanol, initial central nervous system actions. Pharmacol. Rev. 41, 489-537.
41. Del Toro E., Juiz J., Peng X., Lindstrom J., and Criado M. (1994) Immunocytochemical localization of the a7 subunit of the nicotinic acetylcholine receptor in the rat central nervous system. J. Comp. Neurol. 349, 325-342.
42. Dichter M. (1994) Epilepsy, in Biological Basis of Brain Function and Disease (Frazer A., Molinoff P., and Winokur A., eds.), Raven, New York, pp. 406-423.
43. Donnelly-Roberts D., Xue J., Arneric S., and Sullivan J. (1996) In vitro neuroprotective activator (ChCA) ABT-418. Brain Res. 719, 36-44.
44. Drachman D. (1994) Myasthenia gravis. N. Engl. J. Med. 330, 1797-1810.
45. Drachman D., Okumura S., Adams R., and McIntosh K. (1996) Oral tolerance in myasthenia gravis. Ann. NY Acad. Sci. 778, 258-272.
46. Dursun S., Reveley M., Bird R., and Stirton F. (1992) Long lasting improvement of Tourette's syndrome with transdermal nicotine. Lancet 344, 1577.
47. Eisile J., Bertrand S., Galzi J., Devillers-Thiery A., Changeux J., and Bertrand D. (1993) Chimaeric nicotinic-serotonergic receptor combines distinct ligand binding and channel specificities. Nature 366, 479-483.
48. Elgoyhen A., Johnson D., Boulter J., Vetter D., and Heinemann S. (1994) α9, An acetylcholine receptor with novel pharmacological properties expressed in rat cochlear hair cells. Cell 79, 705-715.
49. Engel A. (1994) The neuromuscular junction, in Myology 2nd ed., vol. 1 (Engel A. and Franzini-Armstrong C., eds.), McGraw Hill, New York, pp. 261-302.
50. Engel A., Hutchinson D., Nakano S., Murphy L., Griggs R., Gu Y., Hall Z., and Lindstrom J. (1993a) Myasthenic syndromes attributed to mutations affecting the ε subunit of the acetylcholine receptor. Ann. NY Acad. Sci. 681, 496-508.
51. Engel A., Uchitel O., Walls T., Nagel A., Harper C., and Bodensteiner J. (1993b) Newly recognized congenital myasthenic syndrome associated with high conductance and fast closure of the acetylcholine receptor channel. Ann. Neurol. 34, 38-47.
52. Engel A., Ohno K., Bouzat C., Sine S., and Griggs R. (1996a) End plate acetylcholine receptor deficiency due to nonsense mutations in the ε subunit. Ann. Neurol. 40, 810-817.
53. Engel A., Ohno K., Milone M., Wang H., Nakano S., Bouzat C., Pruitt J., Hutchinson D., Brengman J., Bren N., Sieb J., and Sine S. (1996b) New mutations in acetylcholine receptor subunit genes reveal heterogeneity in the slow channel congenital myasthenic syndrome. Human Mol. Genetics 5, 1217-1227.
54. Engel A., Ohno K., Milone M., and Sine S. (1997) Congenital myasthenic syndromes caused by mutations in acetylcholine receptor genes. Neurology 48 (Suppl. 5), S28-S35.
55. Everitt B. and Robbins T. (1997) Central cholinergic systems and cognition. Annu. Rev. Psychol. 48, 649-684.
56. Evers A. and Steinbach J. (1997) Supersensitive sites in the central nervous system. Anesthesiology 86, 760-762.
57. Flood P., Ramirez-Latorre J., and Role L. (1997) α4β2 neuronal nicotinic acetylcholine receptors in the central nervous system are inhibited by isoflurane and propofol, but α7-type nicotinic acetylcholine receptors are unaffected. Anesthesiology 86, 859-865.
58. Flores C., Rogers S., Pabreza L., Wolfe B., and Kellar K. (1992) A subtype of nicotinic cholinergic receptor in rat brain is composed of α4 and β2 subunits and is upregulated by chronic nicotine treatment. Mol. Pharmacol. 41, 31-37.
59. Forsayeth J. and Kobrin E. (1997) Formation of oligomers containing the β3 and β4 subunits of the rat nicotinic receptor. J. Neurosci. 17, 1531-1538.
60. Franks N. and Lieb W. (1994) Molecular and cellular mechanisms of general anesthesia. Nature 367, 607-614.
61. Freedman R., Coon H., Myles-Worsley M., Orr-Urtreger A., and Olincey A. (1997) Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc. Natl Acad. Sci. USA 94, 587-592.
62. Freedman R., Hall M., Adler L., and Leonard S. (1995) Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biopsychology 38, 22-33.
63. Fu D. and Sine S. (1994) Competitive antagonists bridge α-γ subunit interface of the acetylcholine receptor through quaternary aromatic interactions. J. Biol. Chem. 269, 26,152-26,157.
64. Fu D. and Sine S. (1996) Asymmetric contribution to the conserved disulfide loop to subunit oligomerization and assembly of the nicotinic acetylcholinereceptor. J. Biol. Chem. 271, 31,479-31,484.
65. Fuchs P. (1996) Synaptic transmission at vertebrate hair cells. Curr. Opin. Neurobiol. 6, 514-519.
66. Fucile S., Napolitano M., and Mattei E. (1997) Cholinergic stimulation of human microcitoma cell line H69. Biochem. Biophys. Res. Commun. 230, 501-504.
67. Furness J. and Costa M. (1987) The Enteric Nervous System. Churchill Livingstone, New York.
68. Galzi V. and Changeux V. (1994) Neurotransmitter-gated ion channels as unconventional allosteric proteins. Curr. Opin. Struct. Biol. 4, 554-565.
69. Galzi J., Bertrand D., Devillers-Thiery A., Revah F., Bertrand S., and Changeux J. (1991) Functional significance of aromatic amino acids from three peptide loops of the α7 neuronal nicotinic receptor site investigated by site directed mutagenesis. FEBS Lett. 294, 198-202.
70. Galzi J., Devillers-Thiery A., Hussy N., Bertrand S., Changeux J., and Bertrand D. (1992) Mutations in the channel domain of a neuronal nicotinic receptor convert ion selectivity from cationic to anionic. Nature 359, 500-505.
71. Galzi J., Revah F., Black D., Goeldner M., Hirth C., and Changeux J. (1990) Identification of a novel amino acid alpha tyrosine 93 within the cholinergic ligand-binding sites of the acetylcholine receptor by photoaffinity labeling. J. Biol. Chem. 265, 10,430-10,437.
72. Galzi J., Revah F., Bouet F., Menez A., Coeldner M., Hirth C., and Changeux J. (1991) Allosteric transitions of the acetylcholine receptor probed at the amino acid level with a photolabile cholinergic ligand. Proc. Natl. Acad. Sci. USA 88, 5051-5055.
73. Garcia-Guzman M., Sala F., Sala S., Campos-Caro A., Stuhmer W., Gutierrez L., and Criado M. (1995) abungarotoxin-sensitive nicotinic receptors on bovine chromaffin cells, molecular cloning, functional expression and alternative splicing of the α7 subunit. Eur. J. Neurosci. 7, 647-655.
74. Gattenlohner S., Brabletz T., Schultz A., Marx A., Muller-Hermelink H., and Kirchner T. (1994) Cloning of a cDNA coding for the acetylcholine receptor α subunit from a thymoma associated with myasthenia gravis. Thymus 23, 103-113.
75. Gerzanich V., Anand R., and Lindstrom J. (1994) Homomers of α8 subunits of nicotinic receptors functionally expressed in Xenopus oocytes exhibit similar channel but contrasting binding site properties compared to α7 homomers. Mol. Pharmacol. 45, 212-220.
76. Gerzanich V., Kuryatov A., Anand R., and Lindstrom J. (1997) "Orphan" α6 nicotinic AChR subunit can form a functional heteromeric acetylcholine receptor. Mol. Pharmacol. 51, 320-327.
77. Gomez C., Bhattacharyya B., Charnet P., Day J., Labarca C., Wollmann R., and Lambert E. (1996) A transgenic mouse model of the slow-channel syndrome. Muscle and Nerve 19, 79-87.
78. Gomez C. and Gammack J. (1995) A leucine to phenylalanine substitution in the acetylcholine receptor ion channel in a family with the slow channel syndrome. Neurology 45, 982-985.
79. Gomez C., Maselli R., Gammack J., Lasalde J., Tamamizu S., Cornblath D., Lehar M., McNamee M., and Kuncl R. (1996) A β subunit mutation in the acetylcholine receptor channel gate causes severe slow channel syndrome. Ann. Neurol. 39, 712-723.
80. Gopalakrishnan M., Buison B., Tourna E., Giordano T., Campbell J., Hu J., Donnelly-Roberts D., Arneric S., Bertrand D., and Sullivan J. (1995) Stable expression and pharmacological properties of the human α7 nicotinic acetylcholine receptor. Eur. J. Pharmacol. 290, 237-246.
81. Gopalakrishnan M., Monteggia L., Anderson D., Molinari E., Piattoni-Kaplan M., Donnelly-Roberts D., Arneric S., and Sullivan J. (1996) Stable expression, pharmacologic properties and regulation of the human neuronal nicotinic acetylcholine α4β2 receptor. J. Pharamcol. Exp. Ther. 276, 289-297.
82. Gotti C., Briscini L., Vergerio C., Oortgiesen M., Balestra B., and Clementi F. (1995) Native nicotinic acetylcholine receptors in human Imr32 neuroblastoma cells, functional, immunological, and pharmacological properties. Eur. J. Neurosci. 7, 2083-2092.
83. Grando S., Horton R., Pereira E., Diethelmokita B., George P., Albuquerque E., and Contifine B. (1995) A nicotinic acetylcholine receptor regulating cell adhesion and motility is expressed in human keratinocytes. J. Invest. Dennatol. 105, 774-781.
84. Grando S., Horton R., Mauro T., Kist D., Lee T., and Dahl M. (1996) Activation of keratinocyte nicotinic cholinergic receptors stimulates calcium influx and enhances cell differentiation. J. Invest. Dermatol. 107, 412-418.
85. Gray R., Rajan A., Radcliffe K., Yakehiro M., and Dani J. (1996) Hippocampal synaptic transmission enhanced by low concentrations of nicotine. Nature 383, 713-716.
86. Green J., Thomas G., Rhodes J., Evans B., Russell M., Feyerabend C., Fuller G., Newcombe R., and Sandborn W. (1997) Pharmacokinetics of nicotine carbomer enemas, a new treatment for ulcerative colitis. Clin. Pharmacol.Ther. 61, 340-348.
87. Guslandi M. and Tittpbello A. (1996) Pilot trial of nicotine patches as an alternative to corticosteroids. J. Gastroenterol. 31, 627-629.
88. Hara H., Hayashi K., Ohta K., Itoh N., and Ohta M. (1993) Nicotinic acetylcholine receptor mRNAs in myasthenic thymuses. Biochem. Biophys. Res. Commun. 194, 1269-1275.
89. Henningfield J. (1984) Behavioral pharmacology of smoking, in Advances in Behavioral Pharmacology, vol. 4 (Thompson T., Deros P., and Barrett J., eds.), Academic, Orlando, FL, pp. 131-210.
90. Henningfield J., Chail L., and Griffith R. (1984) Effects of ethanol on cigarette smoking by volunteers without histories of alcoholism. Psychopharmacology 82, 1-5.
91. Hardy J. (1997) The Alzheimer family of diseases, many etiologies, one pathogenesis? Proc. Natl. Acad. Sci. USA 94, 2095-2097.
92. Horch H. and Sargent P. (1995) Perisynaptic surface distribution of multiple classes of nicotinic acetylcholine receptors on neurons in the chicken ganglion. J. Neurosci. 15, 7778-7795.
93. Horch H. and Sargent P. (1996) Synaptic and extrasynaptic distribution of two distinct populations of nicotinic acetylcholine receptor clusters in the frog cardiac ganglion. J. Neurocytol. 25, 67-77.
94. Hsu Y., Amin J., Weiss D., and Wecker L. (1996) Sustained nicotine exposure differentially affects α3β2 and α4β2 neuronal nicotinic receptors expressed in Xenopus oocytes. J. Neurochem. 66, 667-675.
95. Hucho F., Oberthur W., and Lottspeich F. (1986) The ion channel of the nicotinic acetylcholine receptor is formed by the homologous helices MII of the receptor subunits. FEBS Lett. 205, 137-142.
96. Hughes J. and Hatsukami D. (1986) Signs and symptoms of tobacco withdrawal. Arch. Gen. Psych. 43, 289-294.
97. Kao P. and Karlin A. (1986) Acetylcholine receptor binding site contains a disulfide crosslink between adjacent half-cystinyl residues. J. Biol. Chem. 261, 8085-8088.
98. Karlin A. and Akabas M. (1995) Toward a structural basis for the function of nicotinic acetylcholine receptors and their cousins. Neuron 15, 1231-1244.
99. Karlin A., Holtzman E., Yodh N., Label P., Wall J., and Hainfeld J. (1983) The arrangement of the subunits of the acetylcholine receptor of Torpedo californica. J. Biol. Chem. 258, 6678-6681.
100. Kennedy L. (1996) Nicotinic therapy for ulcerative colitis. Ann. Pharmacother. 30, 1022-1023.
101. Keyser K., Britto L., Schoepfer R., Whiting P., Cooper J., Conroy W., Brozozowska-Pretchtl A., Karten H., and Lindstrom J. (1993) Three subtypes of αbungarotoxin-sensitive nicotinic acetylcholine receptors are expressed in chick retina. J. Neurosci. 13, 442-454.
102. Kihara T., Shimohama S., Sawada H., Kimura J., Kume T., Kochiyama H., Maeda T., and Akaike A. (1997) Nicotinic receptor stimulation protects neurons against β amyloid toxicity. Ann. Neurol. 42, 159-163.
103. Koop C. (1988) The health consequences of smoking. Nicotine addiction. A report of the Surgeon General, U.S. Dept. of Health and Human Services.
104. ++ permeability, conductance, and gating of human α4β2 nicotinic acetylcholine receptors, J. Neurosci., in press.
105. Lang B., Waterman S., Pinto A., Janes D., Boot J., Vincent A., and Newsome-David J. (1997) The role of autoantibodies in Lambert-Eaton myasthenic syndrome (LEMS). Ann. NY Acad. Sci. IX International Conference on Myasthenia Gravis and Related Disorders, in press.
106. Lange K., Wells F., Jenner P., and Marsden P. (1993) Altered muscarinic and nicotinic receptor densities in cortical and subcortical regions in Parkinson's disease. J. Neurochem. 60, 197-203.
107. ++ ions in nicotinic facilitation of GABA release in mouse thalamus. J. Neurosci. 17, 576-586.
108. Lennon V., Griesmann G., Sciamanna M., and Wieben E. (1997) Lung carcinoma, cation channel autoimmunity and paraneoplastic myasthenic syndromes. Ann. NY Acad. Sci. IX International Conference on Myasthenia Gravis and Related Disorders, in press.
109. LeNovere N. and Changeux J. (1995) Molecular evolution of the nicotinic acetylcholine receptor, an example of a multigene family in excitable cells. J. Mol. Evol. 40, 155-172.
110. LeNovere N., Zoli M., and Changeux J. (1996) Neuronal nicotinic receptor α6 subunit mRNA is selectively concentrated in catecholaminergic nuclei of the rat brain. Eur. J. Neurosci. 8, 2428-2439.
111. Leonard S., Adams C., Breese C., Adler L., Bickford P., Byerley W., Coon H., Griffith J., Miller C., Myles-Worsley M., Nagamoto H., Rollins Y., Stevens K., Waldo M., and Freedman R. (1996) Nicotinic receptor function in schizophrenia. Schizophren. Bull. 22, 431-445.
112. Lindstrom J. (1996) Neuronal nicotinic acetylcholine receptors, in Ion Channels, vol. 4 (Toshio N., ed.), Plenum, New York, pp. 377-450.
113. Lindstrom J., Anand R., Peng X., Gerzanich V., Wang F., and Li Y. (1995) Neuronal nicotinic receptor subtypes, in Functional Diversity of Interacting Receptors, vol. 757 (Lajtha A., and Abood L., eds.), New York Academy of Science, New York, pp. 100-116.
114. Lindstrom J., Merlie J., and Yogeeswaran B. (1979) Biochemical properties of acetylcholine receptor subunits from Torpedo californica. Biochemistry 18, 4465-4470.
115. Lindstrom J., Peng X., Kuryatov A., Lee E., Anand R., Gerzanich V., Wang F., Wells G., and Nelson M. (1997) Molecular and antigenic structure of nicotinic acetylcholine receptors, Ann. NY Acad. Sci. Proceedings of IX International Conference on Myasthenia Gravis and Related Disorders, in press.
116. Lindstrom J., Shelton G., and Fujii Y. (1988) Myasthenia gravis. Adv. Immunol. 42, 233-284.
117. Lipton S. and Kater S. (1989) Neurotransmitter regulation of neuronal outgrowth plasticity, and survival. TINS 12, 265-270.
118. Little H. (1991) Mechanisms that may underlie the behavioral effects of ethanol. Prog. Neurobiol. 36, 171-194.
119. Lloyd G., Davidson L., and Hornykiewicz O. (1975) The neurochemistry of Parkinson's disease, effect of L-DOPA therapy. J. Pharmacol. Exp. Ther. 195, 453-464.
120. Lloyd G. (1996) Subtype selective nicotinic receptor agonists for the treatment of the motor and non-motor dysfunctions of Parkinson's disease. Movement. Dis. 11, 25.
121. Lukas R. (1991) The effects of chronic nicotinic ligand exposure on functional activity of nicotinic acetylcholine receptors expressed by cells of the PC12 rat pheochromocytoma or the TE671/RD human clonal line. J. Neurochem. 56, 1134-1145.
122. Luther M., Schoepfer R., Whiting P., Blatt Y., Montal M., Montal M., and Lindstrom J. (1989) A muscle acetylcholine receptor is expressed in the human cerebellar medullablastoma cell line TE671. J. Neurosci. 9, 1082-1096.
123. Ma C., Zhang G., Xiao B., Link J., Olsson T., and Link H. (1995) Suppression of experimental autoimmune myasthenia gravis by nasal administration of acetylcholine receptor. J. Neuroimmunol. 58, 51-60.
124. Ma C., Zhang G., Xiao B., Wang Z., Link J., Olsson T., and Link T. (1996) Mucosal tolerance to experimental autoimmune myasthenia gravis is associated with down-regulation of AChR-specific IFN-γ-expressing Th1-like cells and upregulation of TGF-β mRNA in mononuclear cells. Ann. NY Acad. Sci. 778, 273-287.
125. Magleby K. (1996) Neuromuscular transmission, in Myology, 2nd ed., vol. 1 (Engel A. and Franzini-Armstrong C., eds.), McGraw Hill, New York, pp. 442-463.
126. Marks M., Pauly J., Gross D., Deneris E., Hermans-Borgmeyer I., Heinemann S., and Collins A. (1992) Nicotine binding and nicotinic receptor subunit RNA after chronic nicotine treatment. J. Neurosci. 12, 2765-2784.
127. Martin M., Czajkowski C., and Karlin A. (1996) The contribution of aspartyl residues in the acetylcholine receptor γ and δ subunits to the binding of agonists and competitive antagonists. J. Biol. Chem. 271, 13,497-13,503.
128. Martin E., Panickar K., King M., Deyrup M., Hunterm B., Wang G., and Meyer E. (1994) Cytoprotective actions of 2, 4 dimethoxybenzlidene anabaseine in differentiated PC12 cells and septal cholinergic neurons. Drug Develop. Res. 31, 135-141.
129. McGehee D. and Role L. (1995) Physiological diversity of nicotinic acetylcholine receptors expressed by vertebrate neurons. Annu. Rev. Physiol. 57, 521-546.
130. Meldrum B. and Garthwaite J. (1990) Excitatory ammo acid neurotoxicity and neurodegenerative disease. Trends Pharmacol. Sci. 11, 379-387.
131. Menzaghi F., Whelan K., Risbrough V., Rao T., and Lloyd G. (1997a) Effects of a novel cholinergic ion channel agonist SIB-1765F on locomotor activity in rats. J. Pharmacol. Exp. Ther. 280, 384-392.
132. Menzaghi F., Whelan K., Risbrough V., Rao T., and Lloyd G. (1997b) Interactions between a novel cholinergic ion channel agonist, SIB-1765F and L-DOPA in the reserpine model of Parkinson's disease in rats. J. Pharmacol. Exp. Ther. 280, 393-401.
133. Messi M., Renganathan M., Grigorenko E., and Delbono O. (1997) Activation of α7 nicotinic acetylcholine receptor promotes survival of spinal cord motoneurons. FEBS Lett. 411, 32-38.
134. Meyer E., deFiebre C., Hunter B., Simpkins C., Franworth N., and deFiebre N. (1994) Effects of anabaseine-related analogs on rat brain nicotinic receptor binding and on avoidance behaviors. Drug. Develop. Res. 31, 127-134.
135. Mihovilovic M. and Roses A. (1993) Expression of α3, α5, and β4 neuronal acetylcholine receptor subunit transcripts in normal and myasthenia gravis thymus. J. Immunol. 151, 6517-6524.
136. Milone M., Ohno K., and Wang H. (1996) Novel slow channel syndrome due to mutation in the acetylcholine receptor α subunit with increased conductance, nanomolar affinity for acetylcholine, and prolonged open durations of the AChR channel. Ann. Neurol. 40, 956.
137. Morens D., Grandinetti A., Reed D., White L., and Ross G. (1995) Cigarette smoking and protection from Parkinson's disease, false association or etiologic clue. Neurology 45, 1041-1051.
138. Nagata K., Aistrup G., Huang C., Marszalec W., Song J., Yeh J., and Narahashi T. (1996) Potent modulation of neuronal nicotinic acetylcholine receptor channel by ethanol. Neurosci. Letters 217, 189-193.
139. Newhouse P., Potter A., and Lenox E. (1993) The effects of nicotinic agents on human cognition, possible therapeutic applications in Alzheimer's and Parkinson's diseases. Med. Chem. Res. 2, 628-642.
140. Newsome-Davis J. and Vincent A. (1991) Antibody mediated neurological disease. Curr. Opin. Neurobiol. 1, 430-435.
141. Noda M., Furutani Y., Takahashi H., Toyosato M., Tanabe T., Shimizu S., Kikyotani S., Kayano T., Hirose T., Inayama S., and Numa S. (1983) Cloning and sequence analysis of calf cDNA and human genomic DNA encoding α subunit precursor of muscle acetylcholine receptor. Nature 305, 818-823.
142. Ohno K., Hutchinson D., Milone M., Brengman J., Bonzat C., Sine S., and Engel A. (1995) Congenital myasthenia syndrome caused by prolonged acetylcholine receptor channel openings due to a mutations in the M2 domain of the ε subunit. Proc. Natl. Acad. Sci. USA 92, 758-762.
143. Ohno K., Wang H., Milone M., Bren N., Brengman J., Nakano S., Quiram P., Pruitt J., Sine S., and Engel A. (1996) Congenital myasthenic syndrome caused by decreased agonist binding affinity due to a mutation in the acetylcholine receptor ε subunit. Neuron 17, 157-170.
144. Ohno K., Quiram P., Milone M., Wang H., Harper M., Pruitt J., Brengman J., Pao L., Fischbeck K., Crawford T., Sine S., and Engel A. (1997) Congenital myasthenic syndromes due to heteroallelic nonsense/missence mutations in the acetylcholine receptor ε subunit gene, identification and functional characterization of six new mutations. Human Mol. Genet. 6, 753-766.
145. Okamura S., McIntosh K., and Drachman D. (1994) Oral administration of acetylcholine receptor, effects on experimental myasthenia gravis. Ann. Neurol. 36, 704-713.
146. Olale F., Gerzanich V., Kuryatov A., Wang F., and Lindstrom J. (1997) Chronic nicotine exposure differentially affects the function of human α3, α4, and α7 neuronal nicotinic receptor subtypes, submitted for publication.
147. O'Leary M., Filatov G., and White M. (1994) Characterization of d-tubocurarine binding site of Torpedo acetylcholine receptor. Am. J. Physiol. 266, c648-c653.
148. Orr-Urtreger A., Goldmer F., Patrick J., and Beadet A. (1996) Generation of mice deficient in the α7 neuronal nicotinic receptor gene by targeted recombination. Neurosci. Soc. Meeting. Abst. 501, 6.
149. Papke R. (1993) The kinetic properties of neuronal nicotinic receptor genetic basis of functional diversity. Prog. Neurobiol. 41, 509-531.
150. Papke R., deFiebre C., Kem W., and Meyer E. (1994) The subunit specific effects of novel anabasine-derived nicotinic agents, in Alzheimer Disease, Therapeutic Strategies (Giacobini E. and Becker R., eds.), Birkhauser, Boston, MA, pp. 206-211.
151. Pauly J., Marks M., Robinson S., van de Kamp J., and Collins A. (1996) Chronic nicotine and mecamylamine treatment increase brain nicotinic receptor binding without changing α4 or β2 mRNA levels. J. Pharmacol. Exp.Ther. 278, 361-369.
152. Pederson S. and Cohen J. (1990) d-tubcurarine binding sites are located at α-γ and α-δ subunit interfaces of the nicotinic acetylcholine receptor. Proc. Natl. Acad. Sci. USA 87, 2785-2789.
153. Peng X., Anand R., Whiting P., and Lindstrom J. (1994a) Nicotine-induced upregulation of neuronal nicotinic receptors results from a decrease in the rate of turnover. Mol. Pharmacol. 46, 523-530.
154. Peng X., Katz M., Gerzanich V., Anand R., and Lindstrom J. (1994b) Human α7 acetylcholine receptor, cloning of the α7 subunit from the SH-SY5Y cell line and determination of pharmacological properties of native receptors and functional α7 homomers expressed in Xenopus oocytes. Mol. Pharmacol. 45, 546-554.
155. Peng X., Gerzanich V., Anand R., Wang F., and Lindstrom J. (1997) Chronic nicotine treatment upregulates α3 AChRs and α7 AChRs expressed by the human neuroblastoma cell line SH-SY5Y. Mol. Pharmacol. 51, 776-784.
156. Perkins K., Sexton J., and Di Marco A. (1996) Acute thermogenic effects of nicotine and alcohol in healthy male and female smokers. Physiol. and Behav. 60, 305-309.
157. Perry E., Morris C., Court J., Cheng A., Fairbairn A., McKeith I., Irving D., Brown A., and Perry R. (1995) Alteration in nicotine binding sites in Parkinson's disease, Lewy Body Dementia and Alzheimer's disease, possible index of early neuropathology. Neuroscience 64, 385-395.
158. Peto R., Lopez A., Boreham J., Thun M., and Heath C. (1992) Mortality from tobacco in developed countries, indirect estimation from national vital statistics. Lancet 389, 1268-1278.
159. Picciotto M., Zoll M., Lena C., Bessis A., Lallemand Y., LeNovere M., Vincent P., Pich M., Brulet P., and Changeux J. (1995) Abnormal avoidance learning in mice lacking functional high affinity nicotine receptor in the brain. Nature 374, 65-67.
160. Pich E., Pagluisi S., Tessari M., Talabot-Ayer D., Huiysdujnen R., and Chiamulera C. (1997) Common neural sustates for the addictive properties of nicotine and cocaine. Science 275, 83-86.
161. Potthoff A., Ellison G., and Nelson L. (1983) Ethanol intake increases during continuous administration of amphetamine and nicotine, but not several other drugs. Pharmacol. Biochem. Behav. 18, 489-493.
162. Pugh P. and Berg D. (1994) Neuronal acetylcholine receptors that bind abungarotoxin mediate neurite retraction in a calcium-dependent manner. J. Neurosci. 14, 889-896.
163. Quick M. (1995) Growth related role for the nicotinic abungarotoxin receptor, in Effects of Nicotine on Biological Systems II (Clarke P., Quik M., Adlkofer F., Thurau K., eds.), Kirkhauser; Basel, pp. 145-150.
164. Raftery M., Hunkapillar M., Strader C., and Hood L. (1980) Acetylcholine receptor, complex of homologous subunits. Science 208, 1454-1457.
165. Ramirez-Latorre J., Yu C., Qu X., Perin F., Karlin A., and Role L. (1996) Functional contributions of α5 subunit to neuronal acetylcholine receptor channels. Nature 380, 347-351.
166. Rathouz M., Vijayaraghavan S., and Berg D. (1995) Acetylcholine differentially affects intracellular calcium via nicotinic and muscarinic receptors on the same population of neurons. J. Biol. Chem. 270, 14,366-14,375.
167. Reynolds J. and Karlin A. (1978) Molecular weight in detergent solution of acetylcholine receptor from Torpedo californica. Biochemistry 17, 2035-2038.
168. Role L. and Berg D. (1996) Nicotinic receptors in the development and modulation of CNS synapses. Neuron 16, 1077-1085.
169. Romano S., Corriveau R., Schwarz R., and Berg D. (1997a) Expression of the nicotinic receptor α7 gene in tendon and periosteum during early development. J. Neurochem. 68, 640-648.
170. Romano S., Pugh P., McIntosh J., and Berg D. (1997b) Neuronal-type acetylcholine receptors and regulation of α7 gene expression in vertebrate skeletal muscle. J. Neurobiol. 32, 69-80.
171. Rose J., Levin E., Behm F., Westman E., Stein R., Lane J., and Ripka G. (1995) Combined administration of agonist-antagonist as a method of regulating receptor activation. Ann. NY Acad. Sci. 757, 218-221.
172. Sacaan A., Reid R., Santori E., Adams P., Correa L., Mahaffy L., Bleicher L., Cosford N., Stauderman K., McDonald I., Rao T., and Lloyd G. (1997) Pharmacological characterization of SIB-1765F, a novel cholinergic ion channel agonist. J. Pharmacol. Exp. Ther. 280, 373-383.
173. Saedi M., Anand R., Conroy W., and Lindstrom J. (1990) Determination of amino acids critical to the main immunogenic region of intact acetylcholine receptors by in vitro mutagenesis. FEBS Lett. 267, 55-59.
174. Sahakian B., Janes G., Levy M., and Warburton D. (1989) The effect of nicotine on attention, information processing, and short term memory in patients with dementia of the Alzheimer type. Brit. J. Psych. 154, 797-800.
175. Sanberg P., Silver R., Shuttle R., et al. (1997) Nicotine for the treatment of Tourette's syndrome. Pharmacol. Ther. 74, 21-25.
176. Sargent P. (1993) The diversity of neuronal nicotinic acetylcholine receptors. Annu. Rev. Neurosci. 16, 403-443.
177. Sastry R. and Sadavongivad C. (1979) Cholinergic systems in non-nervous tissues. Pharamcol. Rev. 30, 66-132.
178. Scheffer I., Bhatia K., Lopes-Cendes I., Fish D., Marsden C., Andermann E., Desbiens R., Keene D., Cendes F., Manson J., Constantinou J., McIntosh A., and Berkovic S. (1995) Autosomal dominant nocturnal frontal lobe epilepsy. A distinctive clinical disorder. Brain 118, 61-73.
179. Schluep M., Willcox N., Vincent A., Dhoot G., and Newsom-Davis J. (1987) Acetylcholine receptors in human thymic myoid cells in situ, an immunohistological study. Ann. Neurol. 22, 212-222.
180. Schoepfer R., Conroy W., Whiting P., Gore M., and Lindstrom J. (1990) Brain α-bungarotoxin-binding protein cDNAs and mAbs reveal subtypes of this branch of the ligand-gated ion channel superfamily. Neuron 5, 35-48.
181. Schuller H. (1995) Mechanisms of nicotine stimulated cell proliferation in normal and neoplastic neuroendocrine lung cells, in Effects of Nicotine on Biological Systems II (Clarke P., Quick M., Adelkofer F., and Thurau K., eds.), Birkhauser Verlag, Basel, pp. 151-158.
182. Schwartz R. and Kellar K. (1983) Nicotinic cholinergic receptor binding sites in the brain, regulation in vivo. Science 220, 214-216.
183. Seguela P., Wadiche J., Dinnelly-Millet K., Dani J., and Patrick J. (1993) Molecular cloning, functional properties, and distribution of rat brain α7, a nicotinic cation channel highly permeable to calcium. J. Neurosci. 13, 596-604.
184. Sher E. and Clementi R (1997) Neuronal ion channels in lung cancer cells, role in mitogenesis and autoimmunity, Ann. NY Acad. Sci. IX International Conference on Myasthenia Gravis and Related Disorders, in press.
185. Shimohama S., Akaike A., and Kimura J. (1996) Nicotine-induced cholinergic receptor-mediated inhibition of nitric oxide formation. Ann. NY Acad. Sci. 777, 356-361.
186. Silver A., Shytle R., Philip M., and Sanberg P. (1995) Transdermal nicotine in Tourette's syndrome, in Effects of Nicotine on Biological Systems II (Clarke P., Quick M., Adelkofer F., Thurau K., eds.), Birkhauser, Basel, pp. 293-299.
187. Sine S. (1993) Molecular dissection of subunit interfaces in the acetylcholine receptor, identification of residues that determine curare selectivity. Proc. Natl. Acad. Sci. USA 90, 9436-9440.
188. Sine S., Kreienkamp H., Bren N., Maeda R., and Taylor P. (1995) Molecular dissection of subunit interfaces in the acetylcholine receptor, identification of determinants of α-conotoxin M1 selectivity. Neuron 15, 205-211.
189. Sine S., Ohno K., Bouzat C., Auerbach A., Milone M., Pruitt J., and Engel A. (1995) Mutation of the acetylcholine receptors α subunit causes a slow-channel myasthenic syndrome by enhancing agonist binding affinity. Neuron 15, 229-239.
190. Steinlein O., Magnusson A., Stoodt J., Bertrand S., Weiland S., Berkovic S., Nakken K., Propping P., and Bertrand D. (1997) An insertion mutation of the CHRNA 4 gene in a family with autosomal dominant nocturnal frontal lobe epilepsy. Human Mol. Genetics 6, 943-947.
191. Steinlein O., Mulley J., Propping P., Wallace R., Phillips H., Sutherland G., Scheffer I., and Berkovic S. (1995) A missense mutation in the neuronal nicotinic acetylcholine receptor α4 subunit is associated with autosomal dominant nocturnal frontal lobe epilepsy. Nature Genet. 11, 201-203.
192. Swanson L., Simmons D., Whiting P., and Lindstrom J. (1987) Immunohistochemical localization of neuronal nicotinic receptors in the rodent central nervous system. J. Neurosci. 7, 3334-3342.
193. Tarroni P., Rubboli F., Chini B., Zwatt R., Oortgiesen M., Sher E., and Clementi F. (1992) Neuronal-type nicotinic receptors in human neuroblastoma and small cell carcinoma cell lines. FEBS Lett. 312, 66-70.
194. Thomas G. and Rhodes J. (1995) Relationship between smoking, nicotine, and ulcerative colitis, in Effects of Nicotine on Biological Systems II Advances in Pharmacological Sciences (Clarke P., Quick M., Adelkofer F., and Thurau K., eds.), Birkhauser, Boston, pp. 287-291.
195. Tzartos S., Cung M., Demange P., Loutrari H., Mamalaki A., Marraud M., Papadouli I., Sakarellos C., and Tsikaris V. (1991) The main immunogenic region (MIR) of the nicotinic acetylcholine receptor and the anti-MIR antibodies. Mol. Neurobiol. 5, 1-29.
196. Tzartos S., Hochschwender S., Vasquez P., and Lindstrom J. (1987) Passive transfer of experimental autoimmune myasthenia gravis by monoclonal antibodies to the main immunogenic region of the acetylcholine receptor. J. Neuroimmunol. 15, 185-194.
197. Tzartos S., Seybold M., and Lindstrom J. (1982) Specificity of antibodies to acetylcholine receptors in sera from myasthenia gravis patients measured by monoclonal antibodies. Proc. Natl. Acad. Sci. USA 79, 188-192.
198. Ullian E. and Sargent P. (1995) Pronounced cellular diversity and extrasynaptic location of nicotinic acetylcholine receptor subunit immunoreactivities in the chicken pretectum. J. Neurosci. 15, 7012-7023.
199. Unwin N. (1993) Nicotinic acetylcholine receptor at 9Å resolution. J. Mol. Biol. 229, 1101-1124.
200. Unwin N. (1995) Acetylcholine receptor channel imaged in the open state. Nature 373, 37-43.
201. Vemalis A., Conroy W., and Berg D. (1993) Neurons assemble acetylcholine receptors with as many as three kinds of subunits while maintaining subunit segregation among receptor subtypes. Neuron 10, 451-464.
202. ++. Neuron 8, 353-362.
203. Vincent A., Lang B., and Newsom-Davis J. (1989) Autoimmunity to the voltage-gated calcium channel underlies the Lambert-Eaton myasthenic syndrome, a paraneoplastic disorder. TINS 12, 496-502.
204. Vincent A., Newland C., Brueton L., Beeson D., Riemersma S., Huson S., and Newsom-Davis J. (1995) Arthrogryposis multiplex congenita with maternal autoantibodies specific for a fetal antigen. Lancet 346, 24-25.
205. Violet J., Downie D., Nakisa R., Lieb W., and Franks N. (1997) Differential sensitivities of mammalian neuronal and muscle nicotinic acetylcholine receptors to general anesthetics. Anesthesiology 86, 866-874.
206. Wang Z., Hardy S., and Hall Z. (1996) Assembly of the nicotinic acetylcholine receptor. J. Biol. Chem. 271, 27,575-27,584.
207. Wang F., Gerzanich V., Wells G., Anand R., Peng X., Keyser K., and Lindstrom J. (1996) Assembly of human neuronal nicotinic receptor α5 subunits with α3, β2, and β4 subunits. J. Biol. Chem. 271, 17,656-17,665.
208. Wang Z., Huang J., Olsson T., He S., and Link H. (1995) B cell responses to acetylcholine receptor in rats orally tolerized against experimental autoimmune myasthenia gravis. J. Neurol. Sci. 128, 167-174.
209. Wang Z., Link H. Ljungdahl A., Hojeberg B., Link J. He B., Qiao J., Melms A., and Olsson T. (1994) Induction of interferon-γ, interleukin-4, and transforming growth factor-β in rats orally tolerized against experimental autoimmune myasthenia gravis. Cell. Immunol. 157, 353-368.
210. Wang Z., Qiao J., and Link H. (1993a) Suppression of experimental autoimmune myasthenia gravis by oral administration of acetylcholine receptor. J. Neuroimmunol. 44, 209-214.
211. Wang Z., Qiao J., Melms A., and Link H. (1993b) T cell reactivity to acetylcholine receptor in rats orally tolerized against experimental autoimmune myasthenia gravis. Cell. Immunol. 152, 394-404.
212. Watson J. and Lewis R. (1995) Ulcerative colitis response to smoking and to nicotine chewing gum in a patient with α1 anti-trypsin deficiency. Res. Med. 89, 635-636.
213. Weight F., Peoples R., Wright J., Li C., Aguaya L., Lovinger D., and White G. (1993) Neurotransmitter-gated ion channel as molecular sites of alcohol action, in Alcohol, Cell Membranes and Surgical Transduction in Brain (Alling C., Diamond I., and Lelsie S., eds.), Plenum, New York, pp. 107-122.
214. Weiland S., Weitzmann V., Villarroel A., Propping P., and Steinlein O. (1996) An amino acid exchange in the second transmembrane segment of a neuronal nicotinic receptor causes partial epilepsy by altering its desensitization kinetics. FEBS Lett. 398, 91-96.
215. Weiner H. (1997) Oral tolerance for the treatment of autoimmune diseases. Ann. Rev. Med. 48, 341-351.
216. Wenger B., Bryant D., Boyd T., and McKay D. (1997) Evidence for spare nicotinic acetylcholine receptors of a β4 subunit in bovine adrenal chromaffin cells, studies using bromoacetylcholine, epibatidine, cysteine, and mAb35. J. Pharmacol. Exp. Ther. 281, 905-913.
217. Whitehouse P., Matino A., Marcus K., Zweig R., Singer H., Price D., and Kellar K. (1988) Reduction in acetylcholine and nicotine binding in several degenerative diseases. Arch. Neurol. 45, 722-724.
218. Whiting P., Cooper J., and Lindstrom J. (1987) Antibodies in sera from patients with myasthenia gravis do not bind to acetylcholine reeptors from human brain. J. Neuroimmunol. 16, 205-213.
219. Whiting P. and Lindstrom J. (1988) Characterization of bovine and human neuronal nicotinic acetylcholine receptors using monoclonal antibodies. J. Neurosci. 8, 3395-3404.
220. Williamson D., Madans J., Anda R., Kleinman J., Giovino G., and Byers T. (1991) Smoking cessation and severity of weight gain in a national cohort. N. Engl. J. Med. 324, 739-745.
221. Witzemann V., Stein E., Barg B., Konno T., Koenen M., Kues W., Criado M., Hofmann M., and Sakmann B. (1990) Primary structure and functional expression of the α, β, γ, δ, and ε subunits of the acetylcholine receptor from rat muscle. Eur. J. Biochem. 194, 347-448.
222. Wonnacott S. (1997) Presynaptic nicotinic ACh receptors. TINS 20, 92-98.
223. Yu D., Zhang L., Eisele J., Bertrand D., and Changeux J. (1996) Ethanol inhibition of nicotinic acetylcholine type α7 receptors involves the amino-terminal domain of the receptor. Mol. Pharmacol. 50, 1010-1016.
224. Zhang Z., Coggan J., and Berg D. (1996) Synaptic currents generated by neuronal acetylcholine receptors sensitive to α bungarotoxin. Neuron 17, 1231-1240.
225. Zhang L., Oz M., Stewart R., Peoples R., and Weight F. (1997) Volatile general anesthetic actions on recombinant nAChα7, 5-HT3 and chimeric nAChα7-5-HT3 receptors expressed in Xenopus oocytes. Brit. J. Pharmacol. 120, 353-355.